We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Correction: Kao et al. RNF8–CDH1 Co-Expression Predicts Clinical Benefit of Chemoradiotherapy in Triple-Negative Breast Cancer. J. Pers. Med. 2021, 11 , 655.
- Authors
Kao, Chieh-Ni; Moi, Sin-Hua; Hou, Ming-Feng; Luo, Chi-Wen; Chen, Fang-Ming; Pan, Mei-Ren
- Abstract
RNF8-CDH1 Co-Expression Predicts Clinical Benefit of Chemoradiotherapy in Triple-Negative Breast Cancer. RNF8-CDH1 Co-Expression Predicts Clinical Benefit of Chemoradiotherapy in Triple-Negative Breast Cancer. A Significant Correlation Among RNF8, SNAI1, and CDH1 mRNA Expression in Patients with Breast Cancer.
- Subjects
TRIPLE-negative breast cancer; CHEMORADIOTHERAPY
- Publication
Journal of Personalized Medicine, 2022, Vol 12, Issue 3, p466
- ISSN
2075-4426
- Publication type
Correction Notice
- DOI
10.3390/jpm12030466